FDA panel selectively recommends Merck antiviral COVID-19 pill

By Christopher Hutton

Published December 1, 2021 1:21pm ET

Add Washington Examiner on Google

FDA panel selectively recommends Merck antiviral COVID-19 pill — In this Thursday, Feb. 28, 2013 photo, a Merck logo is placed on scientist's lab coat in West Point, Pa. Merck & Co. reports quarterly financial results before the market opens on Wednesday, Feb. 5, 2014. (AP Photo/Matt Rourke) | Matt Rourke

A Food and Drug Administration panel has selectively recommended Merck’s COVID-19 antiviral pill, paving the way for approval.

A panel of doctors organized by the FDA voted 13-10 to recommend that the agency authorize Merck’s antiviral pill, named molnupiravir, for public use Tuesday, finding the known and potential benefits of the new treatment outweigh the possible risks.

Print subscriber? Click here to login/register your account

Digital subscriber? Click here to login/register your account.

Trusted reporting.Unlimited access.

Subscribe for full access to Washington Examiner coverage, expert political analysis, and subscriber-only journalism.

Get Unlimited Access

Already a member? Log in

Cancel anytime.

Tag:

COVID-19 FDA Merck Pfizer